Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers
- PMID: 9487247
- DOI: 10.1093/rheumatology/37.1.27
Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers
Abstract
The administration of moderate to high doses of corticosteroids is associated with bone loss. This probably results from the uncoupling of bone formation (decreased) and bone resorption (unchanged or increased). We examined the effect of low-dose (10 mg/day) prednisone (LDP) and the possible mitigating effects of calcium and 1.25 (OH)2 vitamin D (calcitriol) on calcium and bone metabolism in eight healthy, young male volunteers. The study consisted of four observation periods: in the first period, LDP was prescribed during 1 week; in the second, third and fourth periods, calcium (500 mg/day), calcitriol (0.5 micrograms b.i.d.) and calcium in combination with calcitriol, respectively, were added to LDP. Bone formation was measured by means of serum osteocalcin, carboxy-terminal propeptide of type 1 procollagen (P1CP) and alkaline phosphatase, bone resorption by means of urinary excretion of calcium, hydroxyproline, (free and total) pyridinoline, (free and total) deoxypyridinoline and serum carboxy-terminal cross-linked telopeptide of type 1 collagen (1CTP). Dietary calcium and sodium intake were maintained at a stable level during the entire study period. Treatment with LDP led to a decrease in osteocalcin, P1CP and alkaline phosphatase (all P < 0.01). Urinary excretion of pyridinolines, hydroxyproline and serum 1CTP did not increase, but remained unchanged or slightly reduced (P < 0.05), depending on the time of measurement and the marker of bone resorption. Parathyroid hormone (PTH) (insignificantly) increased during LDP (+19%) and LDP plus calcium (+14%), but decreased during supplementation with calcitriol (-16%) and calcium/calcitriol (-44%; P < 0.01). Urinary excretion of calcium increased during treatment with LDP and calcitriol (P < 0.05) and calcium/calcitriol (P < 0.05). It is concluded that LDP has a negative effect on bone metabolism, since bone formation decreased while bone resorption remained unchanged or decreased slightly. The increase in PTH during LDP could be prevented by calcitriol combined with calcium supplementation.
Similar articles
-
Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.Bone. 1998 Sep;23(3):297-302. doi: 10.1016/s8756-3282(98)00097-0. Bone. 1998. PMID: 9737353 Clinical Trial.
-
Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.Miner Electrolyte Metab. 1996;22(4):219-23. Miner Electrolyte Metab. 1996. PMID: 8807625
-
Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.Ann Rheum Dis. 1996 May;55(5):288-93. doi: 10.1136/ard.55.5.288. Ann Rheum Dis. 1996. PMID: 8660101 Free PMC article.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Biochemical markers of bone turnover: an update.Neth J Med. 1994 Feb;44(2):65-72. Neth J Med. 1994. PMID: 8208326 Review.
Cited by
-
Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis.J Bone Miner Metab. 2013 May;31(3):262-73. doi: 10.1007/s00774-012-0413-x. Epub 2012 Dec 30. J Bone Miner Metab. 2013. PMID: 23274351
-
Bisphosphonates and glucocorticoid-induced osteoporosis: cons.Endocrine. 2015 Aug;49(3):628-34. doi: 10.1007/s12020-015-0639-1. Epub 2015 Jun 4. Endocrine. 2015. PMID: 26041376 Free PMC article. Review.
-
A Woman with Rheumatoid Arthritis and a Bilateral Fracture of the Proximal Tibia.Case Rep Orthop. 2016;2016:5094906. doi: 10.1155/2016/5094906. Epub 2016 Feb 11. Case Rep Orthop. 2016. PMID: 26981298 Free PMC article.
-
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.Osteoporos Int. 2008 Dec;19(12):1683-704. doi: 10.1007/s00198-008-0660-9. Epub 2008 Jul 16. Osteoporos Int. 2008. PMID: 18629570
-
Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.J Endocrinol Invest. 2019 Jul;42(7):859-865. doi: 10.1007/s40618-018-0992-z. Epub 2018 Dec 5. J Endocrinol Invest. 2019. PMID: 30519958
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical